Skip to content
OpenCapital
Get started

Anika Therapeutics ANIK GB — PP&E (Net)

Other geography segments

US
$37.96M—
IT
$1M—

Similar metrics at other companies

Neogen logo
NEOGGB — PP&E (Net)
$12.51M-34.9%
Luxfer Holdings logo
LXFRGB — PP&E (Net)
$33.7M0.0%
MarketAxess logo
MKTXGB — PP&E (Net)
$9.6M-18.2%
Flywire Corporation logo
FLYWGB — PP&E (Net)
$57K+7.5%
SBH
SBHGB — PP&E (Net)
$12.23M+35.0%
EyePoint, Inc. logo
EYPTGB — PP&E (Net)
$0—

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%—

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Anika Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's gb — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's GB — PP&E (net)?
Anika Therapeutics (ANIK) reported GB — PP&E (net) of $2K in Q4 2025.
What does GB — PP&E (net) mean?
This metric represents the net book value of tangible long-term assets, such as manufacturing facilities, machinery, and equipment, specifically allocated to the GB geographic segment. It reflects the capital investment required to support production and operational capabilities within this region after accounting for accumulated depreciation. Investors use this figure to assess the scale of physical infrastructure and the intensity of capital deployment necessary to sustain the company's orthopedic product manufacturing and distribution in this market.